Akbas, HalitYalcin, KendalIsi, HilmiSimsek, SeldaAtay, Ahmet EnginBudak, Turgay2024-04-242024-04-2420121300-02922146-9040https://doi.org/10.5336/medsci.2011-26395https://hdl.handle.net/11468/20091Objective: We aimed to prospectively evaluate the effects of pegylated interferon alpha-2a and alpha-2b therapy on chromosomal aberrations and mitotic index in patients with chronic hepatitis B. Material and Methods: Fifty patients with chronic hepatitis B who underwent pegylated interferon alpha-2a or 2b therapy were evaluated for chromosomal aberrations and mitotic index before the treatment and at the end of 6 months of therapy. Results: Cytogenetic examinations revealed out that there was no significant difference between pre- and post-treatment frequencies of mitotic index and chromosomal aberrations. Conclusion: Interferon alpha-2a and alpha-2b therapy which is associated with common hematologic adverse effects has no significant cytogenetic effect.eninfo:eu-repo/semantics/openAccessHepatitis BInterferon Alfa-2aInterferon Alfa-2bChromosome AberrationsMitotic IndexArticle32615541559WOS:0003141450000092-s2.0-8486831754610.5336/medsci.2011-26395Q4N/A